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VIEWPOINT

Can repurposing drugs play a role in malaria control?
Roland A. Cooper1 and Laura Kirkman2

Innovative drug treatments for malaria, optimally with novel targets, are needed to combat the threat of parasite drug
resistance. As drug development efforts continue, there may be a role for a host-targeting, repurposed cancer drug
administered together with an artemisinin combination therapy that was shown to improve the speed of recovery from a
malaria infection.
faster resolution of fevers and parasitemia
with no additional adverse events. These
results are especially intriguing given the
nature of artemisinin resistance, in which,
following treatment, parasites remain in the
infected host for an extended period of time
(WHO, 2020).
Artemisinin and its derivatives are
highly potent antimalarial drugs notable for
their fast killing of multiple parasite stages.
In general, the use of artemisinin is associated with rapid resolution of clinical symptoms and clearance of parasitemia in
uncomplicated malaria and decreased mortality in severe disease. For this reason, reports of treatment failures with ACTs in
western Cambodia starting over a decade
ago alarmed the global health community.
Decreased efﬁcacy of artemisinin, likely
from earlier extensive use as monotherapy,
led to the emergence of resistance to partner
drugs. In many areas of the Greater Mekong
Subregion (GMS), piperaquine failures are
now common, such that guidelines have
changed and lumefantrine has increasingly
become the partner drug of choice (Hamilton
et al., 2019). Resistance to the artemisinin
component of ACTs is deﬁned clinically as
a delayed parasite clearance time, meaning parasites are still observable after 72 h
in peripheral blood by microscopy (WHO,
2020). Currently, >80% of infections in the
GMS are noted to have a prolonged parasite
clearance half-life and are strongly association with polymorphisms in the parasite

protein P. falciparum Kelch 13 (Pfkelch13;
WHO, 2020; Rosenthal, 2021). The dominant GMS Pfkelch13 polymorphism, C580Y,
has also emerged independently in Guyana
and Papua New Guinea, though with unclear clinical relevance (Mathieu et al.,
2020; Miotto et al., 2020). Recent studies from Africa, in particular Rwanda and
Uganda, are of great concern, as emergence
and expansion of PfKelch13 mutations associated with both in vitro and in vivo resistance was recently reported (Balikagala
et al., 2021; Miotto et al., 2020; Rosenthal,
2021). Emergence of clinically relevant artemisinin resistance in Africa and the subsequent inevitable partner drug failure in
areas with the heaviest burden of disease
would be catastrophic for malaria control
(Rosenthal, 2021).
The optimal response to growing ACT
failure is hotly debated. To date, there are
a limited number of antimalarial agents
available with an even fewer number of
molecular targets, which makes the idea of a
host target so intriguing (Fig. 1). Novel antimalarials, some with new targets, are in
the development pipeline but are unlikely to
be available within the next 5 yr and are
often susceptible to rapidly arising drug
resistance. Increasing the duration of ACT
usage from 3 to 5 d appears to be effective,
but anticipated poor compliance to the extended therapy may exacerbate resistance.
Recent studies assessed the potency and
safety of triple ACTs (TACT), combining an
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Reduction in the global burden of malaria
has stalled over the past several years. In
2019, there were ∼229 million cases in
87 malaria-endemic countries, resulting in an
estimated 386,000 fatalities (WHO, 2020).
The impact of the ongoing COVID-19 pandemic on malaria control has yet to be determined; however, there is great concern
that the diversion of funds, interventions, and
supplies will only lead to increased malaria
morbidity and mortality (Weiss et al., 2021).
Emerging and widespread parasite drug resistance has already complicated malaria
control. Resistance to the components of artemisinin combination therapies (ACTs), the
worldwide standard treatment for Plasmodium falciparum malaria, is a serious concern
in Southeast Asia, and the inevitable loss of
efﬁcacy of these treatments in Africa must be
delayed for as long as possible.
A persistently high burden of disease
demands a rethinking of malaria control,
including the development of new drug
combinations to treat malaria. A potential
novel approach to treatment was recently
described by Chien et al. (2021). They
demonstrated that targeting a host protein
with a repurposed cancer drug may serve as
an adjunctive treatment to the standard of
care, in this case dihydroartemisinin/piperaquine for uncomplicated P. falciparum
malaria infection. In a small study performed in Vietnam, they found that the
addition of the tyrosine kinase inhibitor
(TKI) imatinib to the standard of care led to
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ACT with a second partner drug, typically
meﬂoquine or amodiaquine, both of which
target the food vacuole but have their own
well-documented resistance liabilities (van
der Pluijm et al., 2020). Thus, there is
great potential beneﬁt for a repurposed, affordable antimalarial with a mechanism independent of the other ACT components as
part of a TACT regimen, especially if such a
novel agent could forestall the further development and spread of artemisinin resistance.
Repurposing existing drugs has been
proposed as an approach to hasten the
identiﬁcation and study of novel therapeutics. However, the reality of the impact of
repurposed drugs has been limited to date,
and there are potentially many pitfalls while
proposing new uses for old drugs (Pessanha
de Carvalho et al., 2021; Begley et al., 2021).
Antibiotics that target the specialized parasite
Cooper and Kirkman
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organelle of prokaryotic origin, the apicoplast, have been repurposed to be part
of second-line malaria treatment options
(Biddau and Sheiner, 2019; Pessanha de
Carvalho et al., 2021) and chemoprevention but continue to play an important role
in malaria control (Fig. 1). The greatest
success in drug repurposing for an infectious disease is not pathogen targeting, but
host immune response directed. Thalidomide is used to treat a particular complication of leprosy marked by an overactive
immune response, termed erythema nodosum leprosum (Begley et al., 2021).
Targeting a host protein would be a
unique mechanism of action for an antimalarial drug. Work to deﬁne the mechanism
of action of host TKI against P. falciparum
was extensively explored in the laboratory
before testing efﬁcacy in the ﬁeld. The ﬁrst

TKI approved by the Food and Drug Administration for management of chronic
myelogenous leukemia (CML), imatinib,
was shown to have activity against P. falciparum in vitro (Kesely et al., 2020). TKIs
remain the ﬁrst-line therapy for chronic
phase CML with the exception of pregnant
women (Hochhaus et al., 2017). Thus, there
is widespread experience with these agents,
and in general, patients tolerate TKIs for
long-term treatment with well-described
side effect proﬁles. Side effects during
short-term treatment for falciparum malaria are likely to be minimal but remain to
be studied outside an exclusively adult male
population (Chien et al., 2021).
Laboratory-based studies revealed that
malaria parasites are unable to egress from
their host RBC when cultures are treated
with TKIs (Pantaleo et al., 2017). Treatment
Journal of Experimental Medicine
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Figure 1. Current antimalarial drugs and putative targets. Many antimalarials such as quinolines have well-deﬁned targets, including the food vacuole
where they interfere with hemoglobin digestion or the cyclins that target the parasite apicoplast. The artemisinins cause widespread cellular damage once
activated inside the parasite. Imatinib targets a human tyrosine kinase in the host cell that phosphorylates the RBC membrane protein Band 3 as the cell ages
and during parasite maturation. When phosphorylation of Band 3 is inhibited by imatinib, Band 3 fails to cluster and the RBC membrane remains resistant to
parasite rupture, entrapping the daughter merozoites that would normally infect new RBCs.
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combination with ACTs. Of particular importance is whether the faster parasite
clearance or reduction in fever would persist with different ACT dosing and currently
recommended regimens using lumefantrine, amodiaquine, or pyronaridine as the
partner drug, for example. Safety data from
use in CML are well established, yet additional safety data for malaria treatment are
needed from larger trials, especially in
women and children, the two groups most
heavily affected by malaria. Women who
have clinical immunity to malaria are
known to be at risk of more severe disease
during pregnancy-associated malaria. For
this reason, intermittent preventative treatment with various antimalarials during
pregnancy is known to improve outcomes
for both mother and child (Kakuru et al.,
2020). Imatinib is associated with increased fetal abnormalities and miscarriage
and is not recommended for pregnant or
nursing women. Inability to use this agent in
women of childbearing age is an important
limitation to consider. Similarly, safety in
children needs to be considered, as the majority of malaria deaths occur in children
under 5 yr of age. Finally, in Africa, where
the malaria burden is the highest, host immunity often plays a critical role in parasite
clearance, and ACTs generally remain highly
effective in the region (Djimdé et al., 2003).
The beneﬁt of imatinib toward parasite
clearance in these populations with varying
degrees of immunity needs to be studied.
Malaria is currently a treatable disease,
and we must be creative and diligent to assure the availability of new, efﬁcacious
therapies. Novel approaches are needed as
the threat of drug resistance grows. Imatinib has the advantage of being a novel
affordable agent that has a unique mechanism of action. Importantly, as its target is
host derived, it should be less likely to fail
due to the development of parasite resistance. Malaria researchers will need to
study and consider how to use agents such
as imatinib that are not treatments on their

own but may enhance the action of current
therapy to forestall the emergence and potential spread of additional drug resistant
malaria, in a safe and cost-effective manner. The encouraging ﬁndings from the
ﬁeld warrant further studies on imatinib
and other host-targeting approaches for
malaria.
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with imatinib and other TKIs block changes
to the host RBC membrane that occur during
parasite development, in particular changes
to a protein called Band 3, an abundant integral RBC membrane protein that has
multiple functions including membrane
stabilization. As the RBC ages, Band 3 forms
clusters that destabilize the membrane; this
process is accelerated under conditions of
oxidative damage and during malaria parasite development (Pantaleo et al., 2017;
Shimo et al., 2015). Band 3 phosphorylation
is required for clustering but is blocked
when a host tyrosine kinase (SYK; spleen
tyrosine kinase) is inhibited by imatinib
(Fig. 1). Previous work has shown that by
preventing the phosphorylation of Band 3,
the membrane destabilization needed for
the mature parasite to egress from the RBC
and continue the erythrocytic cycle of infection is blocked. The parasites remain viable but stuck within in the host cell,
theoretically prolonging parasite exposure
to their own toxic metabolites (Kesely et al.,
2020; Pantaleo et al., 2017). When tested in
combination, imatinib was shown to be
synergistic with artemisinin in vitro
(Tsamesidis et al., 2020). In the clinical trial
reported by Chien et al. (2021), the faster
reduction in parasitemia observed in the dihydroartemisinin/piperaquine plus imatinib
arm is potentially meaningful in an area
where prolonged clearance time is a harbinger of ACT failure. Though they found only
one patient infected with a parasite bearing a
PfKelch13 mutation, other parasite factors
can lead to prolonged parasite clearance and
predate the full emergence of PfKelch13mediated treatment failure. Parasite resistance to TKIs, on the other hand, are at least
theoretically unlikely to emerge, as P. falciparum lack their own tyrosine kinases that
could serve as an imatinib target.
While this novel therapeutic approach
coupled more rapid parasite clearance and
faster reduction of fever, many questions
must be addressed before imatinib should
be considered for more widespread use in
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